Controlled trial of methotrexate versus CH-1504 in the treatment of rheumatoid arthritis.
Level II
Where this comes from
- Record sourced from PubMed, PMID 16652417.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To investigate the clinical efficacy, safety, tolerability, and toxicity profile of a metabolically stable antifolate, CH-1504, compared to methotrexate (MTX) in the treatment of rheumatoid arthritis (RA). A 24-week open-label trial of MTX and CH-1504 was performed in 20 patients with RA. Improvements in clinical and laboratory indicators were observed in both study groups. Improvement in the CH-1504 group was greater than in the MTX group. Both treatments were generally well tolerated; however, the liver function test abnormalities and gastrointestinal related adverse events expected with this class of medication were not seen with CH-1504. CH-1504 appears to be clinically efficacious and may possess a superior safety and tolerance profile compared to MTX.
Medical subject headings
- Aminopterin
- Antirheumatic Agents
- Arthritis, Rheumatoid
- Folic Acid Antagonists
- Methotrexate